APA (7th ed.) Citation

Yamazaki, K., Ariyoshi, N., Miyauchi, H., Ohira, G., Kaneya, N., Yamamoto, K., . . . Ishii, I. (2019). A randomized controlled, open‐label early phase II trial comparing incidence of FOLFIRI.3‐induced diarrhoea between Hangeshashinto and oral alkalization in Japanese patients with colorectal cancer. Journal of Clinical Pharmacy & Therapeutics, 44(6), 946. https://doi.org/10.1111/jcpt.13020

Chicago Style (17th ed.) Citation

Yamazaki, Kaori, et al. "A Randomized Controlled, Open‐label Early Phase II Trial Comparing Incidence of FOLFIRI.3‐induced Diarrhoea Between Hangeshashinto and Oral Alkalization in Japanese Patients with Colorectal Cancer." Journal of Clinical Pharmacy & Therapeutics 44, no. 6 (2019): 946. https://doi.org/10.1111/jcpt.13020.

MLA (9th ed.) Citation

Yamazaki, Kaori, et al. "A Randomized Controlled, Open‐label Early Phase II Trial Comparing Incidence of FOLFIRI.3‐induced Diarrhoea Between Hangeshashinto and Oral Alkalization in Japanese Patients with Colorectal Cancer." Journal of Clinical Pharmacy & Therapeutics, vol. 44, no. 6, 2019, p. 946, https://doi.org/10.1111/jcpt.13020.